Related Experiment Video
Updated: Jul 14, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Vascular endothelial growth factor in patients with psoriatic arthritis
A M Fink1, E Cauza, W Hassfeld
1Department of Dermatology, Wilhelminenspital, Vienna, Austria. astrid.fink@wienkav.at
Clinical and Experimental Rheumatology
|June 5, 2007
Summary
Vascular endothelial growth factor (VEGF) is significantly elevated in active psoriatic arthritis patients compared to inactive disease and healthy controls. VEGF levels correlate with disease activity markers in psoriatic arthritis.
Area of Science:
- Rheumatology
- Immunology
- Biochemistry
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory disease.
- Vascular endothelial growth factor (VEGF) plays a role in angiogenesis and inflammation.
- VEGF's role in PsA pathogenesis requires further elucidation.
Purpose of the Study:
- To quantify serum VEGF levels in active PsA, inactive PsA, and healthy controls.
- To investigate the correlation between VEGF levels and clinical/laboratory features in active PsA.
Main Methods:
- Serum samples collected from 14 active PsA patients, 14 inactive PsA patients, and 9 healthy controls.
- Vascular endothelial growth factor (VEGF) concentrations measured using sensitive sandwich ELISA.
Main Results:
- Mean serum VEGF was significantly higher in active PsA (394.4 pg/ml) versus inactive PsA (200.4 pg/ml) and controls (214.3 pg/ml).
- VEGF levels in inactive PsA were comparable to controls (p=0.659).
- In active PsA, VEGF positively correlated with ESR, HAQ, PASI, and VAS.
Conclusions:
- Serum VEGF is a potential biomarker for active psoriatic arthritis.
- Elevated VEGF reflects disease activity in PsA.
